相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions
Abolfazl Maghrouni et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells
Bing-zhou Xue et al.
STEM CELL RESEARCH & THERAPY (2021)
The influence of patient sex on clinical approaches to malignant glioma
Silvia Matteoni et al.
CANCER LETTERS (2020)
Immunotherapy for glioma: Current management and future application
Shengchao Xu et al.
CANCER LETTERS (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
Catherine Hanna et al.
NEURO-ONCOLOGY (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas
Qing Zhang et al.
CELL DEATH & DISEASE (2020)
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential
Na Song et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells
Riccardo Bazzoni et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells
Qing Zhang et al.
CELL AND BIOSCIENCE (2020)
Human Glioblastoma-Derived Mesenchymal Stem Cell to Pericytes Transition and Angiogenic Capacity in Glioblastoma Microenvironment
Dongye Yi et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Durable complete responses in some recurrent highgrade glioma patients treated with Toca 511+Toca FC
Timothy F. Cloughesy et al.
NEURO-ONCOLOGY (2018)
The IFN-gamma/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Jiawen Qian et al.
JOURNAL OF NEUROINFLAMMATION (2018)
CD90 determined two subpopulations of glioma-associated mesenchymal stem cells with different roles in tumour progression
Qing Zhang et al.
CELL DEATH & DISEASE (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Identification of two distinct mesenchymal stromal cell populations in human malignant glioma
Andreas Svensson et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression
Lindsay C. Davies et al.
STEM CELLS (2017)
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Song Xue et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587
Javier Figueroa et al.
CANCER RESEARCH (2017)
Interactions between mesenchymal stem cells and the immune system
Na Li et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Matthias Preusser et al.
NATURE REVIEWS NEUROLOGY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway
Anwar Hossain et al.
STEM CELLS (2015)
Immunobiology of mesenchymal stem cells
S. Ma et al.
CELL DEATH AND DIFFERENTIATION (2014)
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Christine E. Engeland et al.
MOLECULAR THERAPY (2014)
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Ying Wang et al.
NATURE IMMUNOLOGY (2014)
Mesenchymal stem cells generate a CD4+CD25+ Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells
Patricia Luz-Crawford et al.
STEM CELL RESEARCH & THERAPY (2013)
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Adam Wu et al.
NEURO-ONCOLOGY (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide
Guangwen Ren et al.
CELL STEM CELL (2008)
Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4(+)CD25(high)FOXP3(+) regulatory T cells
Zohair Selmani et al.
STEM CELLS (2008)
Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis
Yaojiong Wu et al.
STEM CELLS (2007)
Bone marrow mesenchymal stem cefls induce division arrest anergy of activated T cells
S Glennie et al.
BLOOD (2005)
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
M Di Nicola et al.
BLOOD (2002)
分享论文
